Using ovarian platelet-rich plasma to improve IVF outcomes for women with diminished ovarian reserve
Ovarian Platelet-Rich Plasma Injections for Diminished Ovarian Reserve Patients: A Double-Blinded Placebo-Control Trial
NA · Generation Next Fertility · NCT05790655
This study is testing if injections of platelet-rich plasma can help women aged 35 to 42 with low egg supply have better success with IVF and achieve pregnancy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 230 (estimated) |
| Ages | 35 Years to 42 Years |
| Sex | Female |
| Sponsor | Generation Next Fertility (other) |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05790655 on ClinicalTrials.gov |
What this trial studies
This prospective, double-blinded, randomized placebo-controlled trial investigates whether ovarian injections of platelet-rich plasma (oPRP) can enhance IVF outcomes in women aged 35 to 42 diagnosed with diminished ovarian reserve (DOR). Participants will undergo IVF with preimplantation genetic testing for aneuploidy (PGT-A) and will be randomly assigned to receive either oPRP or a placebo serum injection. The study will monitor participants through baseline assessments, ovulation induction, and subsequent embryo transfer cycles to evaluate the effectiveness of the treatment. The aim is to determine if oPRP can improve the chances of pregnancy and live birth in this population.
Who should consider this trial
Good fit: Ideal candidates are women aged 35 to 42 with a clinical diagnosis of diminished ovarian reserve and poor ovarian response.
Not a fit: Patients with premature ovarian failure or menopause, as well as those under 35 or over 42 years of age, will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve pregnancy rates for women with diminished ovarian reserve undergoing IVF.
How similar studies have performed: While the use of platelet-rich plasma in reproductive medicine is emerging, this specific approach for diminished ovarian reserve is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of diminished ovarian reserve * Clinical diagnosis of poor ovarian response * Women age 35-42 Exclusion Criteria: * Clinical diagnosis of premature ovarian failure * Clinical diagnosis of menopause. * Under 35 years of age * Over 42 years of age
Where this trial is running
New York, New York
- Generation Next Fertility — New York, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Jesse Hade, MD — Generation Next Fertility
- Study coordinator: Alicia Broussard, PhD
- Email: a.broussard@generationnextfertility.com
- Phone: 3174456958
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Diminished Ovarian Reserve, Ovarian Platelet Rich Plasma, DOR, Ovarian PRP, IVF, PRP, PGT-A, ICSI